Amicus Therapeutics, Inc. (FOLD) SVP Daphne Quimi Sells 8,000 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) SVP Daphne Quimi sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the sale, the senior vice president now directly owns 62,676 shares in the company, valued at $922,590.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Daphne Quimi also recently made the following trade(s):

  • On Thursday, October 12th, Daphne Quimi sold 7,000 shares of Amicus Therapeutics stock. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00.

Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down $0.23 during trading hours on Thursday, reaching $15.44. 1,676,325 shares of the company’s stock traded hands, compared to its average volume of 2,419,200. Amicus Therapeutics, Inc. has a one year low of $5.07 and a one year high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The stock has a market capitalization of $2,570.00, a price-to-earnings ratio of -8.44 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same period in the previous year, the company posted ($0.33) earnings per share. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year. research analysts predict that Amicus Therapeutics, Inc. will post -1.56 EPS for the current year.

A number of equities research analysts have recently weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and set a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a report on Friday, October 6th. Finally, Leerink Swann reissued a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and an average target price of $17.81.

A number of large investors have recently bought and sold shares of the business. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics in the third quarter valued at $154,000. GSA Capital Partners LLP purchased a new stake in Amicus Therapeutics in the third quarter valued at $309,000. Iguana Healthcare Management LLC purchased a new stake in Amicus Therapeutics in the third quarter valued at $905,000. Sterling Capital Management LLC acquired a new position in shares of Amicus Therapeutics in the third quarter worth about $218,000. Finally, Neuberger Berman Group LLC acquired a new position in shares of Amicus Therapeutics in the third quarter worth about $196,000.

TRADEMARK VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2018/01/04/amicus-therapeutics-inc-fold-svp-daphne-quimi-sells-8000-shares.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply